{"id":178436,"date":"2018-11-27T19:13:00","date_gmt":"2018-11-28T00:13:00","guid":{"rendered":"https:\/\/www.panix.com\/~msaroff\/40years\/2018\/11\/27\/the-vampire-squid-abides\/"},"modified":"2018-11-27T19:13:00","modified_gmt":"2018-11-28T00:13:00","slug":"the-vampire-squid-abides","status":"publish","type":"post","link":"https:\/\/www.panix.com\/~msaroff\/40years\/2018\/11\/27\/the-vampire-squid-abides\/","title":{"rendered":"The Vampire Squid Abides"},"content":{"rendered":"<div>Goldman Sachs has made the most reprehensible healthcare decision of the year, which is saying a lot, when they decided that <a href=\"https:\/\/www.cnbc.com\/2018\/04\/11\/goldman-asks-is-curing-patients-a-sustainable-business-model.html\">it makes no sense to invest in cures<\/a>, because if you cure someone, they won&#8217;t buy any more of the drugs.<\/div>\n<p>Basically, they redefined medicine as hooking patients into a lifelong pattern of drug use:<\/p>\n<blockquote><p><span style=\"color: blue;\">Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering &#8220;gene therapy&#8221; treatment: cures could be bad for business in the long run. <\/p>\n<p> &#8220;Is curing patients a sustainable business model?&#8221; analysts ask in an April 10 report entitled &#8220;The Genome Revolution.&#8221;<\/p>\n<p> &#8220;The potential to deliver &#8216;one shot cures&#8217; is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,&#8221; analyst Salveen Richter wrote in the note to clients Tuesday. &#8220;While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.&#8221;<\/span><\/p><\/blockquote>\n<p>F%$# the Vampire Squid.&nbsp; They, and f%$# the whole degenerate for-profit health care system needs to be dismantled root and branch.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Goldman Sachs has made the most reprehensible healthcare decision of the year, which is saying a lot, when they decided that it makes no sense to invest in cures, because if you cure someone, they won&#8217;t buy any more of the drugs. Basically, they redefined medicine as hooking patients into a lifelong pattern of drug &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[368,364,456,463],"class_list":["post-178436","post","type-post","status-publish","format-standard","hentry","tag-corruption","tag-evil","tag-finance","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/178436"}],"collection":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/comments?post=178436"}],"version-history":[{"count":0,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/178436\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/media?parent=178436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/categories?post=178436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/tags?post=178436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}